A Phase 3 interventional study of ALD403 (Eptinezumab) and Placebo in Migraine Disorders, sponsored by Alder Biopharmaceuticals, Inc.. Completed at 145 sites in 13 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-06-09.
Sponsored by Alder Biopharmaceuticals, Inc. (part of H. Lundbeck A/S) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing eptinezumab in Migraine Disorders — 6 open to participants now, 6 under way, 5 of them phase 3. eptinezumab · Migraine Disorders.
Among the 21 studies testing eptinezumab in Migraine Disorders, this one has the largest enrollment, is one of 2 that started in 2016, is one of 13 in phase 3, and was the 5th registered.
1,658 studies on the registry are indexed under Migraine Disorders; 339 are open to participants now.
Browse Migraine Disorders studies →6 of the 21 studies testing eptinezumab in Migraine Disorders are open now, in 11 countries. Recruiting first, the newest first:
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18–65
H. Lundbeck A/S · Sites in United States, Argentina, Canada and 8 more countries
Ages 6–17
H. Lundbeck A/S · Sites in United States, Argentina, Canada and 8 more countries
Ages 6–17
H. Lundbeck A/S · Sites in United States, Argentina, Canada and 8 more countries
Ages 12–17
Dr George Medvedev · Sites in Canada
Ages 19–75
By country, each count listing its studies:
eptinezumab: first FDA approval 2020 (VYEPTI), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,121 is above the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Median enrollment 193 across the 21 interventional studies. Of the 15 that completed or were terminated, 8 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 21 have an industry lead sponsor. The 5 most frequent:
This study is registered under Alder Biopharmaceuticals, Inc., one of the names counted as H. Lundbeck A/S. Under that name alone:
Alder Biopharmaceuticals, Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.
23 studies in Migraine Disorders by H. Lundbeck A/S: 3 open now, 3 under way, 3 of them phase 3. Of 20 finished, 9 (45%) have results posted.
Among the 23 studies in Migraine Disorders by H. Lundbeck A/S, this one has the largest enrollment, is one of 2 that started in 2016, is one of 11 in phase 3, and was the 5th registered.
H. Lundbeck A/S’s Migraine Disorders studies by the year they started, since 2012.
3 of the studies testing eptinezumab in Migraine Disorders that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04965675Phase 3H. Lundbeck A/SA Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine | 2027-03-26 |
| NCT07191145Phase 3Sunnybrook Health Sciences CentreEary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT) | 2027-06-30 |
| NCT05897320Phase 3H. Lundbeck A/SA Study of Eptinezumab in Pediatric Participants With Episodic Migraine | 2027-07-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 21 studies testing eptinezumab in Migraine Disorders, from their registry updates:
Among H. Lundbeck A/S’s 23 in Migraine Disorders:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the efficacy and safety of ALD403 in the prevention of migraine headache in chronic migraineurs.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALD403 (Eptinezumab) Dose Level 1 (IV)
Biological: ALD403 (Eptinezumab)
ALD403 (Eptinezumab) Dose Level 2 (IV)
Biological: ALD403 (Eptinezumab)
Placebo (IV)
Biological: Placebo
Also known as: Eptinezumab-jjmr, Vyepti
Change From Baseline in Monthly Migraine Days
Monthly migraine days are summarized in 28-day intervals, and averaged across Weeks 1-12
Time frame: Week 1-12
75% Migraine Responder Rate
Participants with an average reduction in migraine days of at least 75% over Weeks 1 to 12, as compared with baseline.
Time frame: Week 1-12
75% Migraine Responder Rate - 4 Week
Participants with an average reduction in migraine days of at least 75% over Weeks 1 to 4, as compared with baseline.
Time frame: Week 1-4
50% Migraine Responder Rate
Participants with an average reduction in migraine days of at least 50% over Weeks 1 to 12, as compared with baseline.
Time frame: Week 1-12
Percentage of Participants With a Migraine on the Day After Dosing
The percentage of participants with a migraine on the day after dosing, where Day 0 is treatment Day and Day 1 is the day after dosing.
Time frame: Day 1
Change in Monthly Acute Medication Days
An acute medication migraine day was a day with any triptan or ergotamine use as recorded in the eDiary.
Time frame: Week 1-12
Change From Baseline of Headache Impact Test (HIT-6) Score
The HIT-6 measures the impact of headache on the participant's functional health and well-being in 6 domains: pain; role functioning (ability to carry out usual activities); social functioning; energy or fatigue; cognition; and emotional distress assessed over the prior 12-week period. The total possible scores range from 36 (no impact) to 78 (worst impact).
Time frame: Baseline to Week 12
Change in Migraine Prevalence From Baseline to Week 4
The avarage change in percentage of participants with a migraine on any given day during baseline and the equivalent avarage rate over Weeks 1-4.
Time frame: Baseline to Week 4
75% Headache Responder Rate
Participants with an average reduction in headache days of at least 75% over Weeks 1 to 12, as compared with baseline.
Time frame: Week 1-12
50% Headache Responder Rate
Participants with an average reduction in headache days of at least 50% over Weeks 1 to 12, as compared with baseline.
Time frame: Week 1-12
100% Migraine Responder Rate
For each 4-week period the 100% response is determined, and the result for a participant is the average rate across Weeks 1-12. If a participant has one 4-week period out of 3 with 100% response, they are included as 33%.
Time frame: Week 1-12
100% Headache Responder Rate
For each 4-week period the 100% response is determined, and the result for a participant is the average rate across Weeks 1-12. If a participant has one 4-week period out of 3 with 100% response, they are included as 33%.
Time frame: Week 1-12
Change From Baseline in Monthly Migraine Days (Weeks 13-24)
Monthly migraine days are summarized in 28-day intervals, and averaged across Weeks 13-24.
Time frame: Week 13-24
Change From Baseline in Monthly Headache Days (Weeks 1-12)
Monthly headache days are summarized in 28-day intervals, and averaged across Weeks 1-12.
Time frame: Week 1-12
Time to First Migraine After Dosing
The time to first migraine after dosing based upon the migraine data entered into the eDiary
Time frame: 32 weeks
Change From Baseline to Week 12 in Percentage of Migraines With Use of Acute Medication
The percentage of migraines with acute medication usage. Participants with no migraine will be included with a rate of zero.
Time frame: Week 1-12
Change From Baseline to Week 12 in Percentage of Headaches With Use of Acute Medication
The percentage of headaches with acute medication usage. Participants with no headaches will be included with a rate of zero.
Time frame: Week 1-12
Percent Change in Frequency of Migraine Days - Week 1-12
The percent change in frequency of migraine days from Weeks 1-12 was calculated as the number of migraine days within 4-week intervals that were then averaged up to Week 12. The difference of this estimate from baseline was calculated as the change from baseline in the frequency of migraine days over Weeks 1-12.
Time frame: Week 1-12
Percent Change in Frequency of Headache Days - Week 1-12
The percent change in frequency of headache days from Weeks 1-12 was calculated as the number of headache days within 4-week intervals that were then averaged up to Week 12. The difference of this estimate from baseline was calculated as the change from baseline in the frequency of headache days over Weeks 1-12.
Time frame: Week 1-12
Change From Baseline in Percentage of Severe Migraines
The change from baseline in percentage of migraines that are classified as severe over Weeks 1-12.
Time frame: Week 1-12
Change From Baseline in Percentage of Severe Headache
The change from baseline in percentage of headaches that are classified as severe over Weeks 1-12.
Time frame: Week 1-12
Change From Baseline in Monthly Migraine Hours, Weeks 1-12
Migraine hours are the sum of migraines within 4 week intervals, and the average 4 week duration within 12 weeks.
Time frame: Week 1-12
Change From Baseline in Monthly Headache Hours, Weeks 1-12
Headache hours are the sum of the duration of headaches within 4 week intervals, and the average 4 week duration within 12 week intervals.
Time frame: Week 1-12
Duration of Migraine-Free Intervals
The number of participants with migraine-free intervals starting within the first 2 weeks of treatment. The longest migraine free interval for each participant is recorded.
Time frame: 32 weeks
Change From Baseline of Short Form Health Survey (SF-36 v 2.0) Scale Scores
The SF-36 is a health survey containing 36 questions consisting of eight scaled scores to measure quality of life over the past 4 weeks. All scales are on a range of 0 to 100, with 0 being the worst and 100 being the best. Scales are reported separately. Increases from baseline indicate improvement.
Time frame: Baseline to Week 12
Patient Global Impression of Change (PGIC) at Week 12
The PGIC includes a single question concerning the participant's impression of the change in their disease status since the start of the study. Seven responses are possible: Very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse.
Time frame: Week 12
Health Related Quality of Life (EQ-5D-5L) at Week 12
The EQ-5D-5L is a descriptive system of health-related quality of life states consisting of 5 dimensions/questions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take one of five responses. The responses record five levels of severity (no problems/slight problems/moderate problems/severe problems/extreme problems) within a particular EQ-5D dimension.
Time frame: Week 12
| Milestone | 300 mg ALD403 | 100 mg ALD403 | Placebo |
|---|---|---|---|
| Started | 374 | 372 | 375 |
| Participants treated | 350 | 356 | 366 |
| Completed | 322 | 324 | 325 |
| Not completed | 52 | 48 | 50 |
| Withdrew: Adverse event | 6 | 0 | 1 |
| Withdrew: Lack of efficacy | 6 | 5 | 10 |
| Withdrew: Lost to follow-up | 9 | 10 | 17 |
| Withdrew: Physician decision | 0 | 2 | 1 |
| Withdrew: Withdrawal by subject | 9 | 16 | 11 |
| Withdrew: Study burden | 8 | 7 | 3 |
| Withdrew: Other | 14 | 8 | 7 |
Monthly migraine days are summarized in 28-day intervals, and averaged across Weeks 1-12
| Migraine Days | 300 mg ALD403 | 100 mg ALD403 | Placebo |
|---|---|---|---|
| Change From Baseline in Monthly Migraine Days | -8.2 (-23 to 11) | -7.7 (-22 to 10) | -5.6 (-25 to 9) |
Participants with an average reduction in migraine days of at least 75% over Weeks 1 to 12, as compared with baseline.
| Participants | 300 mg ALD403 | 100 mg ALD403 | Placebo |
|---|---|---|---|
| 75% Migraine Responder Rate | 116 | 95 | 55 |
Participants with an average reduction in migraine days of at least 75% over Weeks 1 to 4, as compared with baseline.
| Participants | 300 mg ALD403 | 100 mg ALD403 | Placebo |
|---|---|---|---|
| 75% Migraine Responder Rate - 4 Week | 129 | 110 | 57 |
Participants with an average reduction in migraine days of at least 50% over Weeks 1 to 12, as compared with baseline.
| Participants | 300 mg ALD403 | 100 mg ALD403 | Placebo |
|---|---|---|---|
| 50% Migraine Responder Rate | 215 | 205 | 144 |
The percentage of participants with a migraine on the day after dosing, where Day 0 is treatment Day and Day 1 is the day after dosing.
| Percentage of participants | 300 mg ALD403 | 100 mg ALD403 | Placebo |
|---|---|---|---|
| Percentage of Participants With a Migraine on the Day After Dosing | 27.8 | 28.6 | 42.3 |
An acute medication migraine day was a day with any triptan or ergotamine use as recorded in the eDiary.
| Acute Medication Migraine Days | 300 mg ALD403 | 100 mg ALD403 | Placebo |
|---|---|---|---|
| Change in Monthly Acute Medication Days | -3.5 ± 4.62 | -3.3 ± 4.89 | -1.9 ± 4.18 |
The HIT-6 measures the impact of headache on the participant's functional health and well-being in 6 domains: pain; role functioning (ability to carry out usual activities); social functioning; energy or fatigue; cognition; and emotional distress assessed over the prior 12-week period. The total possible scores range from 36 (no impact) to 78 (worst impact).
| score on a scale | 300 mg ALD403 | 100 mg ALD403 | Placebo |
|---|---|---|---|
| Change From Baseline of Headache Impact Test (HIT-6) Score | -7.3 (-40 to 10) | -6.2 (-34 to 10) | -4.5 (-32 to 15) |
The avarage change in percentage of participants with a migraine on any given day during baseline and the equivalent avarage rate over Weeks 1-4.
| percentage of participants with migraine | 300 mg ALD403 | 100 mg ALD403 | Placebo |
|---|---|---|---|
| Change in Migraine Prevalence From Baseline to Week 4 | -29.8 (-32.10 to -27.49) | -27.1 (-29.35 to -24.78) | -18.8 (-21.06 to -16.54) |
Participants with an average reduction in headache days of at least 75% over Weeks 1 to 12, as compared with baseline.
| Participants | 300 mg ALD403 | 100 mg ALD403 | Placebo |
|---|---|---|---|
| 75% Headache Responder Rate | 61 | 49 | 29 |
Participants with an average reduction in headache days of at least 50% over Weeks 1 to 12, as compared with baseline.
| Participants | 300 mg ALD403 | 100 mg ALD403 | Placebo |
|---|---|---|---|
| 50% Headache Responder Rate | 169 | 150 | 95 |
For each 4-week period the 100% response is determined, and the result for a participant is the average rate across Weeks 1-12. If a participant has one 4-week period out of 3 with 100% response, they are included as 33%.
| percent of participants | 300 mg ALD403 | 100 mg ALD403 | Placebo |
|---|---|---|---|
| 100% Migraine Responder Rate | 15.1 | 10.8 | 5.1 |
For each 4-week period the 100% response is determined, and the result for a participant is the average rate across Weeks 1-12. If a participant has one 4-week period out of 3 with 100% response, they are included as 33%.
| Percent of participants | 300 mg ALD403 | 100 mg ALD403 | Placebo |
|---|---|---|---|
| 100% Headache Responder Rate | 3.8 | 2.0 | 1.5 |
Monthly migraine days are summarized in 28-day intervals, and averaged across Weeks 13-24.
| Migraine Days | 300 mg ALD403 | 100 mg ALD403 | Placebo |
|---|---|---|---|
| Change From Baseline in Monthly Migraine Days (Weeks 13-24) | -9.0 ± 6.72 | -8.3 ± 7.03 | -6.4 ± 7.16 |
Monthly headache days are summarized in 28-day intervals, and averaged across Weeks 1-12.
| Headache Days | 300 mg ALD403 | 100 mg ALD403 | Placebo |
|---|---|---|---|
| Change From Baseline in Monthly Headache Days (Weeks 1-12) | -8.8 ± 6.10 | -8.2 ± 5.78 | -6.4 ± 5.99 |
The time to first migraine after dosing based upon the migraine data entered into the eDiary
| days | 300 mg ALD403 | 100 mg ALD403 | Placebo |
|---|---|---|---|
| Time to First Migraine After Dosing | 4.0 (1.0 to 11.0) | 4.0 (1.0 to 9.0) | 2.0 (1.0 to 5.0) |
The percentage of migraines with acute medication usage. Participants with no migraine will be included with a rate of zero.
| percentage of acute medication migraines | 300 mg ALD403 | 100 mg ALD403 | Placebo |
|---|---|---|---|
| Change From Baseline to Week 12 in Percentage of Migraines With Use of Acute Medication | -14.10 ± 28.86 | -9.79 ± 26.78 | -2.82 ± 20.94 |
The percentage of headaches with acute medication usage. Participants with no headaches will be included with a rate of zero.
| percentage of acute medication headaches | 300 mg ALD403 | 100 mg ALD403 | Placebo |
|---|---|---|---|
| Change From Baseline to Week 12 in Percentage of Headaches With Use of Acute Medication | -7.46 ± 23.32 | -3.08 ± 21.31 | -0.16 ± 19.12 |
The percent change in frequency of migraine days from Weeks 1-12 was calculated as the number of migraine days within 4-week intervals that were then averaged up to Week 12. The difference of this estimate from baseline was calculated as the change from baseline in the frequency of migraine days over Weeks 1-12.
| percent change of migraine days | 300 mg ALD403 | 100 mg ALD403 | Placebo |
|---|---|---|---|
| Percent Change in Frequency of Migraine Days - Week 1-12 | -53.5 ± 35.46 | -48.6 ± 36.60 | -34.5 ± 38.17 |
The percent change in frequency of headache days from Weeks 1-12 was calculated as the number of headache days within 4-week intervals that were then averaged up to Week 12. The difference of this estimate from baseline was calculated as the change from baseline in the frequency of headache days over Weeks 1-12.
| percent change of headache days | 300 mg ALD403 | 100 mg ALD403 | Placebo |
|---|---|---|---|
| Percent Change in Frequency of Headache Days - Week 1-12 | -44.1 ± 30.59 | -41.2 ± 29.20 | -31.4 ± 28.62 |
The change from baseline in percentage of migraines that are classified as severe over Weeks 1-12.
| percentage of migraines scored "severe" | 300 mg ALD403 | 100 mg ALD403 | Placebo |
|---|---|---|---|
| Change From Baseline in Percentage of Severe Migraines | -18.17 ± 27.90 | -16.39 ± 26.17 | -10.82 ± 25.73 |
The change from baseline in percentage of headaches that are classified as severe over Weeks 1-12.
| percentage of headaches scored "severe" | 300 mg ALD403 | 100 mg ALD403 | Placebo |
|---|---|---|---|
| Change From Baseline in Percentage of Severe Headache | -14.00 ± 22.50 | -14.01 ± 20.95 | -9.12 ± 22.12 |
Migraine hours are the sum of migraines within 4 week intervals, and the average 4 week duration within 12 weeks.
| migraine hours | 300 mg ALD403 | 100 mg ALD403 | Placebo |
|---|---|---|---|
| Change From Baseline in Monthly Migraine Hours, Weeks 1-12 | -80.9 ± 89.17 | -75.2 ± 90.40 | -52.8 ± 101.82 |
Headache hours are the sum of the duration of headaches within 4 week intervals, and the average 4 week duration within 12 week intervals.
| headache hours | 300 mg ALD403 | 100 mg ALD403 | Placebo |
|---|---|---|---|
| Change From Baseline in Monthly Headache Hours, Weeks 1-12 | -82.5 ± 88.85 | -74.6 ± 84.57 | -54.8 ± 97.15 |
The number of participants with migraine-free intervals starting within the first 2 weeks of treatment. The longest migraine free interval for each participant is recorded.
| Participants | 300 mg ALD403 | 100 mg ALD403 | Placebo |
|---|---|---|---|
| <= 7 days | 132 | 146 | 226 |
| 8-14 days | 86 | 95 | 75 |
| 15-21 days | 38 | 42 | 23 |
| >21 days | 94 | 73 | 42 |
The SF-36 is a health survey containing 36 questions consisting of eight scaled scores to measure quality of life over the past 4 weeks. All scales are on a range of 0 to 100, with 0 being the worst and 100 being the best. Scales are reported separately. Increases from baseline indicate improvement.
| score on a scale | 300 mg ALD403 | 100 mg ALD403 | Placebo |
|---|---|---|---|
| Physical Functioning | 3.3 ± 6.22 | 2.6 ± 5.98 | 1.5 ± 6.88 |
| Role Physical | 6.0 ± 8.46 | 4.6 ± 8.53 | 3.6 ± 8.08 |
| Bodily Pain | 6.2 ± 8.71 | 5.1 ± 9.12 | 4.0 ± 8.55 |
| General Health | 3.5 ± 7.45 | 2.3 ± 6.89 | 0.7 ± 7.53 |
| Vitality | 4.5 ± 9.02 | 4.2 ± 8.84 | 2.3 ± 8.23 |
The PGIC includes a single question concerning the participant's impression of the change in their disease status since the start of the study. Seven responses are possible: Very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse.
| Participants | 300 mg ALD403 | 100 mg ALD403 | Placebo |
|---|---|---|---|
| Very Much Improved | 73 | 54 | 38 |
| Much Improved | 142 | 126 | 92 |
| Minimally Improved | 68 | 82 | 85 |
| No Change | 51 | 69 | 111 |
| Minimally Worse | 3 | 10 | 16 |
| Much Worse | 0 | 2 | 1 |
| Very Much Worse | 0 | 1 | 0 |
The EQ-5D-5L is a descriptive system of health-related quality of life states consisting of 5 dimensions/questions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take one of five responses. The responses record five levels of severity (no problems/slight problems/moderate problems/severe problems/extreme problems) within a particular EQ-5D dimension.
| Participants | 300 mg ALD403 | 100 mg ALD403 | Placebo |
|---|---|---|---|
| Mobility — No problems | 289 | 289 | 298 |
| Mobility — Slight Problems | 41 | 41 | 37 |
| Mobility — Moderate Problems | 8 | 13 | 6 |
| Mobility — Severe Problems | 0 | 1 | 2 |
| Mobility — Extreme Problems | 0 | 0 | 0 |
| Self-care — No problems | 320 | 337 | 331 |
| Self-care — Slight Problems | 13 | 6 | 7 |
| Self-care — Moderate Problems | 5 | 1 | 4 |
| Self-care — Severe Problems | 0 | 0 | 1 |
| Self-care — Extreme Problems | 0 | 0 | 0 |
| Usual Activities — No problems | 227 | 233 | 241 |
| Usual Activities — Slight Problems | 79 | 78 | 71 |
| Usual Activities — Moderate Problems | 27 | 28 | 26 |
| Usual Activities — Severe Problems | 5 | 5 | 4 |
| Usual Activities — Extreme Problems | 0 | 0 | 1 |
| Pain/Discomfort — No problems | 122 | 121 | 130 |
| Pain/Discomfort — Slight Problems | 140 | 127 | 120 |
| Pain/Discomfort — Moderate Problems | 56 | 78 | 75 |
| Pain/Discomfort — Severe Problems | 18 | 14 | 16 |
| Pain/Discomfort — Extreme Problems | 2 | 4 | 2 |
| Anxiety/Depression — No problems | 220 | 227 | 219 |
| Anxiety/Depression — Slight Problems | 91 | 87 | 91 |
| Anxiety/Depression — Moderate Problems | 23 | 25 | 27 |
| Anxiety/Depression — Severe Problems | 4 | 5 | 5 |
| Anxiety/Depression — Extreme Problems | 0 | 0 | 1 |
Collected over Baseline to Week 32 (end of study). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 300 mg ALD403 | 0/350 (0%) | 4/350 (1.1%) | 52/350 (14.9%) |
| 100 mg ALD403 | 0/356 (0%) | 3/356 (0.8%) | 34/356 (9.6%) |
| Placebo | 0/366 (0%) | 3/366 (0.8%) | 42/366 (11.5%) |
| Event | 300 mg ALD403 | 100 mg ALD403 | Placebo |
|---|---|---|---|
| GastroenteritisInfections and infestations | 1/350 | 0/356 | 0/366 |
| FallInjury, poisoning and procedural complications | 1/350 | 0/356 | 0/366 |
| Spinal Compression FractureInjury, poisoning and procedural complications | 1/350 | 0/356 | 0/366 |
| Migraine With AuraNervous system disorders | 1/350 | 0/356 | 0/366 |
| SeizureNervous system disorders | 1/350 | 0/356 | 0/366 |
| Suicide AttemptPsychiatric disorders | 1/350 | 0/356 | 0/366 |
| Gastric UlcerGastrointestinal disorders | 0/350 | 1/356 | 0/366 |
| HaematemesisGastrointestinal disorders | 0/350 | 1/356 | 0/366 |
| Tibia FractureInjury, poisoning and procedural complications | 0/350 | 1/356 | 0/366 |
| MigraineNervous system disorders | 0/350 | 1/356 | 0/366 |
| Event | 300 mg ALD403 | 100 mg ALD403 | Placebo |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 33/350 | 19/356 | 22/366 |
| Upper respiratory tract infectionInfections and infestations | 19/350 | 15/356 | 20/366 |
Safety population includes all participants who received study drug or placebo.
| Age, Continuous(years) | 300 mg ALD403 | 100 mg ALD403 | Placebo | Total |
|---|---|---|---|---|
| Mean | 41.0 ± 10.36 | 41.0 ± 11.72 | 39.6 ± 11.28 | 40.5 ± 11.15 |
| Sex: Female, Male(Participants) | 300 mg ALD403 | 100 mg ALD403 | Placebo | Total |
|---|---|---|---|---|
| Female | 314 | 307 | 325 | 946 |
| Male | 36 | 49 | 41 | 126 |
| Ethnicity (NIH/OMB)(Participants) | 300 mg ALD403 | 100 mg ALD403 | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 18 | 33 | 35 | 86 |
| Not Hispanic or Latino | 332 | 323 | 331 | 986 |
| Unknown or Not Reported | 0 | 00 | 0 | 0 |
| Race (NIH/OMB)(Participants) | 300 mg ALD403 | 100 mg ALD403 | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 1 | 3 |
| Asian | 1 | 1 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 1 |
| Black or African American | 23 | 21 | 38 | 82 |
| White | 322 | 332 | 321 | 975 |
| More than one race | 2 | 1 | 4 | 7 |
| Unknown or Not Reported | 0 | 0 | 1 | 1 |
| Region of Enrollment(participants) | 300 mg ALD403 | 100 mg ALD403 | Placebo | Total |
|---|---|---|---|---|
| Hungary | 3 | 5 | 3 | 11 |
| United States | 195 | 198 | 232 | 625 |
| Czechia | 12 | 7 | 8 | 27 |
| Ukraine | 34 | 43 | 33 | 110 |
| United Kingdom | 3 | 4 | 2 | 9 |
| Spain | 18 | 22 | 18 | 58 |
| Russia | 32 | 27 | 27 | 86 |
| Belgium | 0 | 0 | 1 | 1 |
| Denmark | 3 | 2 | 1 | 6 |
| Italy | 7 | 3 | 5 | 15 |
| Georgia | 36 | 38 | 23 | 97 |
| Slovakia | 4 | 5 | 8 | 17 |
| Germany | 3 | 2 | 5 | 10 |
| Baseline Migraine Days(Participants) | 300 mg ALD403 | 100 mg ALD403 | Placebo | Total |
|---|---|---|---|---|
| Less than 17 days per month | 197 | 199 | 206 | 602 |
| Greater than or equal to 17 days per month | 153 | 157 | 160 | 470 |
| Medication overuse headache diagnosis(Participants) | 300 mg ALD403 | 100 mg ALD403 | Placebo | Total |
|---|---|---|---|---|
| No | 203 | 217 | 221 | 641 |
| Yes | 147 | 139 | 145 | 431 |
Showing the first 100 of 145 sites across 13 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2016 to primary completion in Nov 2017, 12 months.
Results were first posted in Jun 2020, 2 years 7 months after primary completion. A results delay was requested in Sep 2018.
Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 12 months is below that.
Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eptinezumab
Alder Biopharmaceuticals, Inc. →